A Phase 1 Study of LT-002-158 Intended for the Treatment of Skind Disorder in Healthy Adult Volunteers
Status:
Not yet recruiting
Trial end date:
2025-02-10
Target enrollment:
Participant gender:
Summary
LT-002-158 is a novel small molecule drug being developed as a potential therapy for the
treatment of skin disorder disease includes Hidradenitis Suppurativa and Atopic Dermatitis.